Biomedical literature, made navigable
Discover articles through diseases, drugs, treatments, interventions, clinical instruments, institutions and funders extracted from the BMJ open corpus.
An entity family is a category of extracted information. Choose one to browse its named entities and supporting articles.
Organisations named as supporting, sponsoring, or funding research.
5,089 articles · 9,137 mentionsInstitutionsUniversities, hospitals, research centres, networks, and public bodies.
11,350 articles · 22,378 mentionsDrugsNamed medicines, compounds, vaccines, and pharmacological agents.
10,506 articles · 58,393 mentionsDiseasesNamed diseases, disorders, syndromes, injuries, and health conditions.
23,712 articles · 125,551 mentionsTreatmentsClinical therapies and care approaches used to manage a condition.
7,227 articles · 16,644 mentionsInterventionsProgrammes, procedures, policies, and other actions being evaluated.
4,132 articles · 9,994 mentionsClinical instrumentsNamed questionnaires, scales, scores, indices, and other clinical outcome assessments.
945 articles · 1,957 mentionsChoose an entity to see the articles in which it was identified.
…st GI IREAs. Additionally, primary diagnoses (p= 0.032), poorer ECOG performance status (p=0.008), older age (p=0.048) and higher Charleson comorbidity…
…tage III NSCLC who were treated with chemoradiation followed by durvalumab. Data collection included baseline characteristics, treatment p…
…cluded patients who received at least one ICI (e.g., nivolumab, pembrolizumab); Cohort 2 included those who did not. Propensity score matchin…
…e responses, underscoring the urgent need for novel strategies. Lurbinectedin, an approved second-line therapy for SCLC, is being evaluated i…
…e JM, Galffy G, Hochmair M, et al. Perioperative durvalumab for resectable non-small-cell lung cancer. N Engl J Med. 2023 Nov 2;389(18):1672–1684.Cascone T, Awad MM,…
…specific antibody, as monotherapy in patients with antigen-rich solid tumors resistant to anti-PD(L)1: Journal for ImmunoTherapy of Cancer. …
…pre-treatment longitudinal changes following the combination of avelumab with utomilumab (a 4-1BB agonist) (arm A), PF-04518600 (an OX40…
…3-CAR-NK cells resulted in potent antitumor activity in vivo. 1 Multiple myeloma is a plasma cell cancer that develops in the bone marrow and re…
…ector:Target ratio). Significant reduction in tumor burden with EP10 was also observed in A549 (p<0.0001, 2-way ANOVA) and 143B xeno…
…have shown promising efficacy and safety in clinical trials for gastric cancer, but have struggled to achieve complete, durable responses due …
…the Efficacy of A Novel Anti-tMUC1-CAR T Cell Treatment against Pancreatic Ductal Adenocarcinoma. Cells. 2019 Sep 11;8(9):1070.Wilkie S, Picco G, Foster J, Davi…
…an GBM orthotopic model using the GBM01 cell line.Methods Human GBM01 GFP-Luc cells were stereotaxically injected into the brain of N…